Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects

Learn more about:
Related Clinical Trial
Safety and Efficacy of Injectable Poly-L-Lactic Acid for Volume Loss in the Temples Using Dual Plane Injections Exploratory Study of the Relationships Between the Biomarkers of Inflammation, Lipidome and Insulin Resistance and Disorders of Glycemic Regulation in a Cohort of Insulin-resistant Subjects Due to Excess Weight or Dunnigan’s Lipodystrophy Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy Intraoperative Fluid Management of Liposuction , Cardiometry Versus Rohrich Formula The Visceral Adiposity Measurement and Observation Study Evaluating the Performance and Safety of the Medical Device Plenhyage® in the Treatment of Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects Evaluating the Performance and Safety of the Medical Device Janesse in the Treatment of Facial Dermal Tissue Defects Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH. Hemoglobin Level, Coagulopathy Profile and Electrolyte Balance Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome Exercise and Pioglitazone for HIV-Metabolic Syndromes Observational Study of Changes in Fat Distribution and Blood Metabolites in HIV Infected Adults Yoga for the Management of HIV-Metabolic Syndromes Pravastatin for Hyperlipidaemia in HIV. A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth Exercise for Patients With HIV Infections Lactate Metabolism Study in HIV Infected Persons Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells Growth Hormone Dynamics and Cardiac Steatosis in HIV The Effect of Anti-HIV Treatment on Body Characteristics of HIV-Infected Children Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir. Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers Detraining in People Living With HIV/AIDS SHARE: Simple HAART With Abacavir, Reyataz, and Epivir The Effects of Anabolic Steroids and Protease Inhibitors on People Living With HIV/AIDS Observational Study of Fat Loss in HIV Infected Adults Taking Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Metabolism and Body Shape of Healthy Children and Children With Chronic Infections Changing to Nonprotease Inhibitor Treatment to Improve Side Effects Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids Perceived Changes in Body Build and Image in Patients Who Are Now Taking or Recently Have Stopped Taking Anti-HIV Drugs White Light Scanning to Aid Body Contouring: A Pilot Project Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy The Cleveland Cardiometabolic Cohort Metabolic Abnormalities in HIV-infected Persons Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients. Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome Effects of Short-term Growth Hormone in HIV-infected Patients Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid Raltegravir Therapy for Women With HIV and Fat Accumulation The PREFORM Study: A Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Effects of IGF-I in HIV Metabolic Disease Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy Effects of Growth Hormone Releasing Hormone in HIV A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy Body Composition and Adipose Tissue in HIV Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue CONFORM: Rotational Fractional Resection for Submental Contouring Study of Alpha-2 Adrenergic Receptor Dysfunction in Regional Lipoatrophy TH9507 in Patients With HIV-Associated Lipodystrophy TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Energy Expenditure of People Living With HIV/AIDS Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS) Egrifta Replacement and Sleep Disordered Breathing Clinical Trial to Determine the Efficacy of Sculptra™ Dermal Filler for the Correction of Contour Deformities Caused by Lipoatrophy Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients Low Energy Diet and Familial Partial Lipodystrophy Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy Role of the Autonomic Nervous System in HIV-Lipodystrophy Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome Therapeutic Approaches to HAART-Induced Lipodystrophy Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift Leptin to Treat Lipodystrophy Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat Corticosteroid-induced Lipodystrophy and Adipokines Short-term Effects of Leptin in People With Lipodystrophy Leptin to Treat Lipodystrophy Lipodystrophy Connect Patient Registry An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy Autologous Adipose-Derived Stem Cell Transplantation in Patients With Lipodystrophy

Brief Title

Evaluating the Performance and Safety of the Medical Device Auralya® in the Treatment of Facial Dermal Tissue Defects

Official Title

Open, Non-comparative, Multicentre Clinical Investigation to Evaluate the Performance and Safety of the Medical Device Auralya® (Hyaluronic Acid-dermal Filler) in the Treatment of Facial Dermal Tissue Defects

Brief Summary

      The Research Question of the present study is the following: in a population of men and women
      presenting facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects)
      will cross-linked hyaluronic acid (Auralya®) significantly decrease and / or improve their
      appearance, results observed after 4, 8 and 12 weeks?

Detailed Description

      Auralya® action is to increase the volume of dermal-epidermal tissue based on the natural
      ability of hydrophilic hyaluronic acid molecules to bind to an amount of water many times
      greater than their weight. This allows to fill the intradermal spaces and integrate the
      intercellular matrix, conferring turgidity to the tissues. The cross-linking of the
      hyaluronic acid contained in the product has the effect of more stable and durable filling
      over time. These characteristics allow Auralya® to be used as a temporary filler for
      subcutaneous areas to correct small defects in the dermal tissue due to lipodystrophies or
      the presence of fibrotic tissues as scars, caused by pathologies or trauma.

Study Type


Primary Outcome

POSAS score assessed by Investigator and patient

Secondary Outcome

 Global Aesthetic Improvement Scale evaluated by the patient (GAIS)





Study Arms / Comparison Groups

 Auralya 1
Description:  Sixteen patients will be administered Auralya® 1 (Cross-linked Hyaluronic Acid) for the treatment of minor facial dermal tissue defects (scars, depressed plaques, and lipodystrophy defects).


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

March 21, 2022

Completion Date

December 11, 2022

Primary Completion Date

December 11, 2022

Eligibility Criteria

        Inclusion Criteria:

          1. Men or women with age ≥ 18 and ≤ 65 years.

          2. Patients with facial dermal tissue defects (scars, depressed plaques, and
             lipodystrophy defects), caused by both pathologies or trauma, seeking tissue
             augmentation and skin imperfections treatment and willing to receive Hyaluronic Acid

          3. Patients who agree to discontinue any other dermatological treatment and procedures
             during the study.

          4. Patients willing to provide signed informed consent to clinical investigation

          5. Patients able to communicate adequately with the Investigator and to comply with the
             requirements for the entire study.

        Exclusion Criteria:

          1. Past or current bleeding disorders.

          2. Use of aspirin and antiplatelet agents a week prior to treatment.

          3. Prior or planned use of topical injection to the face (steroid, retinoid: applicable
             only to drugs, not applicable to cosmetics), within 4 weeks prior to screening or
             during this study (steroid ointment for therapeutic objectives is allowed for short
             -term use of ≤14 consecutive days.).

          4. Use of immunosuppressive, chemotherapies, or systemic corticosteroids within 12 weeks
             from screening.

          5. History of anaphylaxis or severe complicated allergy symptoms.

          6. Clinically significant cardiovascular, digestive, respiratory, endocrine, or central
             nervous system disorders or previous mental disorders that may significantly affect
             the study.

          7. Known hypersensitivity skin reaction to hyaluronic acid or hypersensitivity skin
             reaction to the investigational device based on intradermal test results at visit 1.

          8. Evidence or history of autoimmune disease or compromised immune system.

          9. Treatment with anticoagulants, thrombolytics, or platelet inhibitors within 1 week
             prior to study participation.

         10. Prior permanent fillers or fat graft procedures around facial dermal tissue defects.

         11. Facial dermal tissue defects correction procedures (e.g., botulinum toxin A injection,
             face lift, soft tissue augmentation, medium-depth peel, dermal photo-rejuvenation,
             etc.) around infraorbital region within 6 months prior to study participation.

         12. History of hypersensitivity to local anaesthetic of amide type or HA.

         13. History of keloid formation or hypertrophic scar on the face.

         14. Evidence of active infection on the face.

         15. Wound, skin disorder or infection around facial dermal tissue defects that may affect
             the efficacy assessment.

         16. Pregnant woman, lactating woman, and man or woman of childbearing potential who is
             planning a pregnancy or is unwilling to use appropriate methods of contraception*
             during the study. *Methods of contraception: hormonal contraceptive, intrauterine
             device or intrauterine system, double barrier method (condom with spermicide/diaphragm
             or cervical cap with spermicide), surgical sterilization (vasectomy, tubal ligation,

         17. Need to exposure to the sun, UV rays and extreme conditions of heat for at least a
             week after the treatment.

         18. Need to have direct or indirect contact with quaternary ammonium salts during the

         19. As with all dermal filler procedures, the product should not be used in vascular rich
             areas. Using the product at sites such as Glabella and nose may inadvertently be
             injected into the blood vessels, resulting in symptom of vessel occlusion such as
             colour vision deficiency and blindness.

         20. Patients with illness, or other medical condition that, in the opinion of the
             investigator, would compromise participation or be likely to lead to hospitalization
             during the study.

         21. Participation in an interventional clinical study or administration of any
             investigational agents in the previous 30 days.




18 Years - 65 Years

Accepts Healthy Volunteers



Mihaela Fratila, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

I.R.A. Istituto Ricerche Applicate S.p.A.


 Opera CRO, a TIGERMED Group Company

Study Sponsor

Mihaela Fratila, Principal Investigator, SCM Dr. Rosu

Verification Date

April 2022